Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2013. The document serves as a notification of transactions involving directors, specifically detailing changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction and does not contain financial performance data.
Material Changes
The only material change disclosed is a transaction by Director Sir Andrew Witty. On June 4, 2013, he purchased one Ordinary Share at a price of 1,706 pence. This purchase resulted from the re-investment of a cash fraction balance held within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of a director's share purchase in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,706 pence per Ordinary Share on June 4, 2013.
- Confirm the total shareholding of Sir Andrew Witty following this transaction.
- Note that this filing does not contain quarterly or annual financial results.